EyeGene Financial Statements From 2010 to 2024
| 185490 Stock | KRW 2,825 5.00 0.18% |
Check EyeGene financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among EyeGene's main balance sheet or income statement drivers, such as , as well as many indicators such as . EyeGene financial statements analysis is a perfect complement when working with EyeGene Valuation or Volatility modules.
EyeGene |
EyeGene Company Shares Outstanding Analysis
EyeGene's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current EyeGene Shares Outstanding | 10.99 M |
Most of EyeGene's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, EyeGene is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, EyeGene has 10.99 M of shares currently outstending. This is much higher than that of the sector and significantly higher than that of the Biotechnology industry. The shares outstanding for all Republic of Korea stocks is notably lower than that of the firm.
EyeGene Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining EyeGene's current stock value. Our valuation model uses many indicators to compare EyeGene value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across EyeGene competition to find correlations between indicators driving EyeGene's intrinsic value. More Info.EyeGene is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value EyeGene by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for EyeGene's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About EyeGene Financial Statements
EyeGene stakeholders use historical fundamental indicators, such as EyeGene's revenue or net income, to determine how well the company is positioned to perform in the future. Although EyeGene investors may analyze each financial statement separately, they are all interrelated. For example, changes in EyeGene's assets and liabilities are reflected in the revenues and expenses on EyeGene's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in EyeGene. Please read more on our technical analysis and fundamental analysis pages.
EyeGene Inc., a biotechnology company, engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. EyeGene Inc. was founded in 2000 and is headquartered in Seoul, South Korea. Eyegene is traded on Korean Securities Dealers Automated Quotations in South Korea.
Pair Trading with EyeGene
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if EyeGene position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in EyeGene will appreciate offsetting losses from the drop in the long position's value.Moving against EyeGene Stock
| 0.69 | 226950 | OliX PharmaceuticalsInc | PairCorr |
| 0.63 | 105560 | KB Financial Group | PairCorr |
| 0.46 | 047810 | Korea Aerospace Indu | PairCorr |
The ability to find closely correlated positions to EyeGene could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace EyeGene when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back EyeGene - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling EyeGene to buy it.
The correlation of EyeGene is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as EyeGene moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if EyeGene moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for EyeGene can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in EyeGene Stock
EyeGene financial ratios help investors to determine whether EyeGene Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in EyeGene with respect to the benefits of owning EyeGene security.